Pursuit Wealth Management LLC Invests $554,000 in Natera, Inc. $NTRA

Pursuit Wealth Management LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,420 shares of the medical research company’s stock, valued at approximately $554,000.

A number of other hedge funds also recently bought and sold shares of NTRA. Robinhood Asset Management LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $12,981,000. JPMorgan Chase & Co. raised its holdings in shares of Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares in the last quarter. Rakuten Investment Management Inc. bought a new position in shares of Natera during the third quarter valued at approximately $34,096,000. New York State Common Retirement Fund lifted its stake in Natera by 63.2% in the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after acquiring an additional 57,400 shares during the period. Finally, SWS Partners lifted its stake in Natera by 11.8% in the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after acquiring an additional 4,980 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 85,299 shares of Natera stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total transaction of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares in the company, valued at approximately $29,504,704.32. This trade represents a 40.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares in the company, valued at approximately $34,035,422.08. This represents a 13.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 314,545 shares of company stock worth $73,141,185 over the last three months. Company insiders own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. William Blair began coverage on shares of Natera in a research report on Tuesday. They set an “outperform” rating on the stock. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. Morgan Stanley cut their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Finally, Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Trading Down 3.5%

NTRA opened at $207.19 on Thursday. The company has a market cap of $29.37 billion, a price-to-earnings ratio of -135.42 and a beta of 1.68. The stock has a fifty day simple moving average of $203.26 and a two-hundred day simple moving average of $211.26. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period in the prior year, the firm earned ($0.41) EPS. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.